Suppr超能文献

腹膜透析患者的长期死亡率和技术生存率:单中心25年回顾性分析

Long-term mortality and technique survival in peritoneal dialysis patients: a 25-year retrospective analysis in a single center.

作者信息

Scarmignan Roberta, Alfano Gaetano, Morisi Niccolò, Fontana Francesco, Mori Giacomo, Ferrarini Marco, Ferri Camilla, Tonelli Laura, Ligabue Giulia, Magistroni Riccardo, Gregorini Mariacristina, Donati Gabriele

机构信息

Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.

Nephrology, Dialysis and Kidney Transplant Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.

出版信息

Clin Kidney J. 2025 Jul 8;18(8):sfaf215. doi: 10.1093/ckj/sfaf215. eCollection 2025 Aug.

Abstract

BACKGROUND

We comprehensively assessed patient survival and the duration of peritoneal dialysis (PD) treatment over a 25-year period within our PD unit.

METHODS

We retrospectively evaluated 497 PD patients who initiated PD between 1996 and 2021. The cohort was divided into three distinct periods based on pivotal events, such as the introduction of more biocompatible dialysis solutions and the initiation of remote monitoring technologies. Kaplan-Meier survival assessments, Cox proportional hazards model and Gray subdistribution hazard model were employed to evaluate patient survival and PD-to-hemodialysis (HD) transfer.

RESULTS

The use of PD as the initial treatment increased significantly over the years. Mean age was 63.5 ± 15.7 years; 61% were male, and 61% had three or more comorbidities including hypertension (81%), dyslipidemia (66%), cardiovascular disease (56%) and diabetes (16%). The five-year mortality rate was 40%. Risk factors for mortality included continuous ambulatory peritoneal dialysis (CAPD) [hazard ratio (HR) = 2.63, 95% confidence interval (CI) 1.76-3.93;  < .001], older age (HR = 2.96, 95% CI 1.98-4.43;  < .001), cardiovascular disease (HR = 1.96, 95% CI 1.31-2.95;  = .001) and the use of renin-angiotensin-aldosterone system inhibitors (RAASi) (HR = 1.81, 95% CI 1.22-2.70;  = .004). At 5 years, 48% of patients remained on PD. In the Cox model, risk factors for PD-to-HD transfer included CAPD (HR = 1.62, 95% CI 1.21-2.16;  = .001). RAASi use (HR = 0.66, 95% CI 0.46-0.94;  = .02) and female sex (HR = 0.70, 95% CI 0.51-0.96;  = .03) were associated with longer PD duration.

CONCLUSIONS

The study provides insights into the changing landscape of PD. Advances in PD solutions and remote monitoring have contributed to changes in PD outcomes and its increased adoption over the years. Given the observational nature of the study, caution is warranted in interpreting the association of both CAPD and RAASi with mortality.

摘要

背景

我们全面评估了我院腹膜透析(PD)科室25年间患者的生存率及PD治疗时长。

方法

我们回顾性评估了1996年至2021年间开始接受PD治疗的497例患者。根据一些关键事件,如引入生物相容性更好的透析液和启动远程监测技术,将该队列分为三个不同时期。采用Kaplan-Meier生存评估、Cox比例风险模型和Gray亚分布风险模型来评估患者生存率及从PD转为血液透析(HD)的情况。

结果

多年来,将PD作为初始治疗的情况显著增加。平均年龄为63.5±15.7岁;61%为男性,61%患有三种或更多合并症,包括高血压(81%)、血脂异常(66%)、心血管疾病(56%)和糖尿病(16%)。五年死亡率为40%。死亡风险因素包括持续性非卧床腹膜透析(CAPD)[风险比(HR)=2.63,95%置信区间(CI)1.76 - 3.93;P<0.001]、年龄较大(HR = 2.96,95%CI 1.98 - 4.43;P<0.001)、心血管疾病(HR = 1.96,95%CI 1.31 - 2.95;P = 0.001)以及使用肾素 - 血管紧张素 - 醛固酮系统抑制剂(RAASi)(HR = 1.81,95%CI 1.22 - 2.70;P = 0.004)。5年后,48%的患者仍在接受PD治疗。在Cox模型中,从PD转为HD的风险因素包括CAPD(HR = 1.62,95%CI 1.21 - 2.16;P = 0.001)。使用RAASi(HR = 0.66,95%CI 0.46 - 0.94;P = 0.02)和女性(HR = 0.70,95%CI 0.51 - 0.96;P = 0.03)与更长的PD治疗时长相关。

结论

该研究为PD格局的变化提供了见解。PD溶液和远程监测的进展促成了PD治疗结果的变化以及多年来其应用的增加。鉴于该研究的观察性本质,在解释CAPD和RAASi与死亡率的关联时应谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07a2/12319534/33a82d85786f/sfaf215fig1g.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验